Enhancement of the anti-neoplastic effects of tamoxifen by somatostatin analogues

Digestion

Volumn 57, Issue , 1996, Pages 29-33

  Pollak, Michael ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Anti oestrogenic agents; Breast cancer; Combination therapy; Octreotide; Somatostatin analogues; Tamoxifen

Indexed keywords

ANTINEOPLASTIC AGENT; OCTREOTIDE; SOMATOMEDIN C; SOMATOSTATIN DERIVATIVE; SOMATOSTATIN RECEPTOR; TAMOXIFEN;

BREAST CANCER; CONFERENCE PAPER; DRUG POTENTIATION; DRUG RECEPTOR BINDING; FEMALE; HUMAN; METASTASIS; PRIORITY JOURNAL; TUMOR CELL;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; DRUG SYNERGISM; ESTROGEN ANTAGONISTS; HORMONE ANTAGONISTS; HUMANS; SOMATOSTATIN; TAMOXIFEN;

EID: 0029931710     PISSN: 00122823     EISSN: 14219867     Source Type: Journal    
DOI: 10.1159/000201389     Document Type: Article

References (37)

1. Lemer L, Jordan VC: Development of antioes-trogens and their use in breast cancer: Eighth Cain Memorial Award Lecture. Cancer Res 1990:50:4177-4189.
2. Reichlin S: Somatostatin. New Engl J Med 1983:309:1495-1501.
3. Patel YC, Srikant CB: Subtype selectivity of peptide analogs for all five cloned human somatostatin receptors (hsstr 1-5). Endocrinology 1994:135:2814-2817.
4. Buscail L, Esteve JP, Saint-Laurent N, Bertand V, Reisinc T, O'Carroll AM, Bell GL Schally AV, Vaysse N, Susini C: Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA 1995:92:1580-1584.
5. Schally AV: Oncological applications of somatostatin analogues. Cancer Res 1988:48: 6877-6885.
6. Weckbecker G, Raulf F, Stolz B, Bruns C: Somatostatin analogues for diagnosis and treatment of cancer. Pharmacol Ther 1993:60:245-264.
7. van Eijck CM, Krenning EP, Bootsma A, Lin-demans J, Jcekel J, Reubi JC, Lamberts SW: Somatostatin-rcceptor scintigraphy in primary breast cancer. Lancet 1994:343:640-643.
8. Buscail L, Delesque N, Estcve JP, Saint-Laurent N, Prats H, Clcrc P, Robbcrecht P, Bell GI, Liebow C, Schally AV: Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: Mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA 1994:91: 2315-2319.
9. Macaulay VM: Insulin-like growth factors and cancer. Br J Cancer 1992:65:311-320.
10. Poliak M, Perdue JF, Margolesc RG, Baer K, Richard M: Presence of somatomedin receptors on primary human breast and colon carcinomas. Cancer Lett 1987:38:223-230.
11. Resricof TM, Abrallam D, Yutanaviboonchai W, Rotman HL, Kajstura J, Rubin R, Zolcck P, Bascrga R: The insulin-like growth factor I receptor protects tumour cells from apoptosis in vivo. Cancer Res 1995;55:2463-2469.
12. Stracke ML, Kohn EC, Aznavoorian SA, Wilson LL, Salomon D, Krutsch HC, Liotta LA, Schiifmann E: Insulin-like growth factors stimulate chcmotaxis in human melanoma cells. Biochcm Biophys Res Commun 1988:153: 1076-1083.
13. Nalio-Hayshi J, Jto H, Kanavasu T, Morita I, Mulola S: Stimulatory effects of insulin and IGF-I on migration and tube formation by vascular endothelial cells. Atherosclerosis 1992: 92:141-149.
14. Poliak M, Polychronakos C, Guyda H: Somatostatin analogue SMS 201-995 reduces serum IGF-I levels in patients with neoplasms potentially dependent on IGF-I. Anticanccr Res 1989;9:889-892.
15. Rcubi JC: A somatostatin analogue inhibits chondrosarcoma and insulinoma tumour growth. Acta Endocrinol 1985:109:108-114.
16. Poliak M, Costantino J, Polychronakos C, Blauer S, Guyda H, Redmond C, Fisher B, Margolese R: Effect of tamoxifen on serum insulin-like growth factor 1 levels in stage I breast cancer patients. J Natl Cancer Inst 1990; 82:1693-1697.
17. Stoll B: Breast cancer risk in Japanese women with special reference to the growth hormonc-insulin-like growth factor axis. Jpn J Clin Oncol 1992;22:1-5.
18. dcWaard F, Comelis J, Aoki K, Yoshida M: Breast cancer incidence according to weight and height in two cities of the Netherlands and in Aichi prefecture. Japan. Cancer 1995:40: 1269-1275.
19. Vatten L, Kvikstad A, Nvmoen E: Incidence and mortality of breast cancer related to body height and living conditions during childhood and adolescence. Eur J Cancer 1992:28:128-131.
20. Murata M, Kuno K, Sakamoto G: Epidemiology of family predisposition for breast cancer in Japan. J Natl Cancer Inst 1982:69:1229-1234.
21. Tretli S: Height and weight in relation to breast cancer morbidity and mortality: A prospective study of 570.000 women in Norway. Int J Cancer 1989:44:23-30.
22. Vatten U, Kvinnsland S: Body height and risk of breast cancer: A prospective study of 23.831 Norwegian women. Br J Cancer 1990:61:881-885.
23. Hunter D, Willett W: Diet, body size, and breast cancer. Epidemiol Rev 1993:15:110-132.
24. Juul A, Bane P, Hertel N, Main K, Dalgaaed P, Jorgensen K, Mullen J, Hall K, Shakkcbaek N: Scrum insulin-like growth factor I in 1030 healthy children, adolescents, and adults: Relation to age. sex. stage of puberty, testicular size, and body mass index. J Clin Endocrinol Metab 1995;78:744-752.
25. Yang X, Beamer W, Huynh H, Poliak M: Reduced growth of human breast cancer xenografts in hosts homozygous for the ‘lit’ mutation. Cancer Res 1996:56:1509-1511.
26. Mondina R, Borscllino G, Poma S, Baroni M, Di Nubila B, Sacchi P: Breast carcinoma and skeletal formation. Eur J Cancer 1992;28A: 1068-1070.
27. Setyono-Han B, Henkelman MS, Foekens JA, KJijn GM: Direct inhibitory effects of somatostatin (analogues) on the growth of human breast cancer cells. Cancer Res 1987;47:1566-1570.
28. Szepeshazi K, Milovanovic S, Lapis K, Groot K, Schally AV: Growth inhibition of oestrogen independent MXT mouse mammary carcinomas in mice treated with an agonist or antagonist of LH-RH. an analog of somatostatin, or a combination. Breast Cancer Res Treat 1992; 21:181-192.
29. Friedl A, Jordan VC, Poliak M: Suppression of serum IGF-I levels in breast cancer patients during adjuvant tamoxifen therapy. Eur J Cancer 1993.29A: 1368-1372.
30. Poliak M: Effects of adjuvant tamoxifen therapy on growth hormone and insulin-like growth factor 1 (IGF-I) physiology: in Salmon SE (ed): Adjuvant Therapy of Cancer. Philadelphia. Lippincott. 1993. vol 7, pp 43-55.
31. Huynh HT, Tctenes E, Wallace L, Poliak M: In vivo inhibition of insulin-like growth factor-I gene expression by tamoxifen. Cancer Res 1993;53:1727-1730.
32. Tannenbaum GS, Gurd W, Lapointe M, Poliak M: Tamoxifen attenuates pulsatile growth hormone secretion: Mediation in part by somatostatin. Endocrinology 1992:130:3395-3401.
33. Malaab SA, Poliak M, Goodvcr CG: Direct effects of tamoxifen on growth hormone secretion by pituitary cells in vitro. Eur J Cancer 1992;28A:788-793.
34. Huynh HT, Poliak M: Enhancement of tamoxifen-induced suppression of insulin-like growth factor I gene expression and serum level by a somatostatin analogue. Biochem Biophvs Res Commun 1994:203:253-259.
35. Poliak M, Ingle J, Suntan V, Kugker J, Nicker-scn T, Deroo B: Enhancement of tamoxifen-induced suppression of serum IGF-1 levels in metastatic breast cancer patients by co-admin-istration of the somatostatin analogue octreotide (abstract 1167). Proc Am Assoc Cancer Res 1996:37.
36. Weckbcckcr G, Tolcsvai L, Stolz B, Poliak M, Bruns C: Somatostatin analogue octreotide enhances the anti-neoplastic effects of tamoxifen and ovariectomy on 7.12-dimethylbenz(a)an-thracene-induced rat mammary carcinomas. Cancer Res 1994:54:6334-6337.
37. Welsch CW: Host factors affecting the growth of carcinogen-induced rat mammary carcinomas: A review and tribute to Charles Brenton Huggins. Cancer Res 1985;45:3415-3443.